Spyre Therapeutics grants 11,138 stock options, 3,195 RSUs to two employees
SYRE•Spyre Therapeutics approved options covering 11,138 shares and 3,195 restricted stock units for two non-executive employees on November 2, 2026, under its 2018 Equity Inducement Plan.
1. Employee awards
The options have a 10-year term and a $95.51 exercise price. They vest 25% on each employee’s first start-date anniversary and then 1/48 monthly, while the RSUs vest 25% annually on anniversaries of the next November 15 on or after each employee’s start date; both awards are subject to continuous service.
